Dual targeting PD-1 and BRD4 with INTASYL self-delivering RNAi elicits persistent anti-tumor immunity in-vivo following complete resolution of tumors.
Annals of Oncology, 2021, Volume 32, Supplement 5. 10.1016/j.annonc.2021.08.1735. Benjamin Cuiffo, Melissa Maxwell, Dingxue Yan, Brianna Rivest, James Cardia and Simon P. Fricker.